Tango Therapeutics, Inc. Current Assets
Tango Therapeutics, Inc. (TNGX) had Current Assets of $1.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-11
- 2026-06-30: Assets, Current $1.03B.
- 2026-03-31: Assets, Current $392.33M.
- 2025-12-31: Assets, Current $353.76M.
- 2025-09-30: Assets, Current $163.78M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.03B 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $392.33M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $353.76M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $163.78M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $190.10M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $224.93M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $266.34M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $300.81M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $328.41M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $352.04M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $346.54M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $370.89M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $320.54M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $343.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $375.27M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $401.67M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $436.08M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $460.65M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $492.34M 10-K · filed 2023-03-27 | |
| 2021-09-30 | $516.34M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $734.29K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.45M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $193.63M 10-K · filed 2022-03-28 | $1.50M 10-K · filed 2021-03-31 |
| 2020-09-30 | $1.62M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |